Article
Warning Letter Quality System Deficiencies — The Top 5 CMC Patterns
Across hundreds of FDA Warning Letters issued to pharmaceutical manufacturers over the past five years, five quality system deficiency patterns appear with such regularity that they constitute a…
XGene Articles & Analysis
Evidence-led analysis for decisions that matter.
Senior-authored regulatory, CMC, GMP, quality, and inspection analysis designed for practical use—not passive reading.
01SignalSource evidence
02InterpretTechnical judgment
03ApplyDecision pathway
Publication library
Keep moving from evidence to decision.
Article
Warning Letter Quality System Deficiencies — The Top 5 CMC Patterns
Across hundreds of FDA Warning Letters issued to pharmaceutical manufacturers over the past five years, five quality system deficiency patterns appear with such regularity that they constitute a…
Article
Residual Solvent Control — ICH Q3C Applied to Multi-Step Synthetic Routes and the Specification Strategy
ICH Q3C is one of the most frequently cited guidance documents in CDER chemistry deficiency letters, and most CMC teams believe they have implemented it correctly because they…
Article
Warning Letter Surveillance Strategy — Using FDA Data as CMC Intelligence
FDA Warning Letters are the most detailed, most current, and most underutilized source of CMC and GMP competitive intelligence available to pharmaceutical companies — and the organizations that…
Article
Elemental Impurities — ICH Q3D Risk Assessment and the CMC Specification Integration in Module 3
ICH Q3D established a risk-based framework for elemental impurity control that allows most pharmaceutical programs to avoid routine elemental testing if the risk assessment demonstrates that elemental impurity…
Article
Inspection Back Room Strategy — CMC Team Coordination Under Pressure
The back room during an FDA inspection is where the outcome is actually determined — the front room is where FDA asks the questions, but the back room…
Article
Nitrosamine Impurities — FDA-EMA Guidance Implementation and the CMC Risk Assessment Framework
Nitrosamine impurities defined a decade of pharmaceutical recalls and regulatory interventions beginning in 2018. The regulatory response — FDA and EMA directives requiring industry-wide risk assessments for all…
Article
Warning Letter Surge Intelligence — Reading FDA’s Coordinated Enforcement Patterns
FDA Warning Letters to drug manufacturers rose roughly 50 to 59 percent year-over-year in FY2025 — and data integrity findings now appear in roughly 15 percent of all…
Article
FDA Guidance Intelligence — PQ-CMC Structured Data (FHIR) Submission Requirements
FDA's Pharmaceutical Quality–CMC structured data program has moved well past the pilot stage — the Stage 2 FHIR Implementation Guide cleared HL7 balloting in early 2025 and is…
Read with purpose
Every analysis should make the next move clearer.
- 01ReadUnderstand the technical argument.
- 02TraceFollow evidence and regulatory context.
- 03CompareExplore related XGene intelligence.
- 04ActConnect the issue to a practical pathway.